Patents by Inventor Yair Reisner

Yair Reisner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10961504
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
  • Patent number: 10933124
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 2, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Eran Ophir, Yaki Eidelstein, Rotem Gidron Budovsky
  • Publication number: 20200289582
    Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.
    Type: Application
    Filed: May 28, 2020
    Publication date: September 17, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Chava ROSEN, Elias SHEZEN, Irit MILMAN KRENTSIS
  • Patent number: 10751368
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 25, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig, Shlomit Reich-Zeliger
  • Patent number: 10668109
    Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: June 2, 2020
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Chava Rosen, Elias Shezen, Irit Milman Krentsis
  • Publication number: 20190358269
    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methods comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 28, 2019
    Applicant: Yeda Research And Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig
  • Publication number: 20190338247
    Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.
    Type: Application
    Filed: January 18, 2018
    Publication date: November 7, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Shlomit REICH-ZELIGER
  • Publication number: 20190328793
    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.
    Type: Application
    Filed: July 11, 2019
    Publication date: October 31, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG
  • Publication number: 20190316087
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 17, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
  • Patent number: 10434121
    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 8, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig
  • Patent number: 10369172
    Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: August 6, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Esther Bachar-Lustig
  • Publication number: 20190091266
    Abstract: A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.
    Type: Application
    Filed: November 22, 2018
    Publication date: March 28, 2019
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Carmit Hillel-Karniel, Chava Rosen, Esther Bachar-Lustig, Elias Shezen
  • Publication number: 20180207247
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, said anti-third party cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation, wherein said cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Application
    Filed: July 14, 2016
    Publication date: July 26, 2018
    Inventors: Yair REISNER, Noga OR-GEVA, Eran OPHIR, Yaki EIDELSTEIN, Rotem GIDRON BUDOVSKY
  • Publication number: 20180207272
    Abstract: An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is disclosed. Methods of generating same and using same are also disclosed.
    Type: Application
    Filed: July 14, 2016
    Publication date: July 26, 2018
    Inventors: Yair REISNER, Noga OR-GEVA, Eran OPHIR, Yaki EIDELSTEIN, Rotem GIDRON BUDOVSKY
  • Publication number: 20180200300
    Abstract: A method of transplantation is disclosed. The method comprising administering to a subject in need of transplantation of cells in suspension, a therapeutically effective amount of tolerance inducing anti-third party cytotoxic T-lymphocytes (CTLs), wherein the tolerance inducing anti-third party CTLs are generated by directing T-lymphocytes of a donor against a third party antigen or antigens, the tolerance inducing anti-third party CTLs being substantially depleted of T-lymphocytes capable of developing into alloreactive CTLs, and wherein the tolerance inducing anti-third party CTLs do not comprise cells having a central memory T-lymphocyte (Tcm) phenotype, wherein the cells in suspension comprise non-hematopoietic cells or hematopoietic cells which are not stem cells. Methods of treating and kits are also provided.
    Type: Application
    Filed: January 18, 2018
    Publication date: July 19, 2018
    Inventors: Yair REISNER, Esther BACHAR-LUSTIG, Shlomit REICH-ZELIGER
  • Publication number: 20180193384
    Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
    Type: Application
    Filed: November 29, 2017
    Publication date: July 12, 2018
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
  • Publication number: 20180169152
    Abstract: A method of conditioning a subject in need of transplantation of progenitor cells in suspension of a tissue of interest is disclosed. The method comprising: (a) administering to a subject a therapeutically effective amount of an agent capable of inducing damage to the tissue of interest, wherein the damage results in proliferation of resident stem cells in the tissue; and subsequently (b) subjecting the subject to an agent which ablates the resident stem cells in the tissue. A method of transplanting progenitor cells in suspension of a tissue of interest to a subject in need thereof is also disclosed.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventors: Yair REISNER, Chava ROSEN, Elias SHEZEN, Irit MILMAN KRENTSIS
  • Patent number: 9833482
    Abstract: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: December 5, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Elias Shezen, Chava Rosen
  • Patent number: 9738872
    Abstract: An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: August 22, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Eran Ophir, Yaki Eidelstein, Esther Bachar-Lustig
  • Patent number: 9610331
    Abstract: Methods of modulating mobilization of cells from the bone marrow are provided. In a specific embodiment there is provided a method of increasing mobilization of hematopoietic precursors from the bone marrow to the peripheral blood in a subject in need thereof, the method comprising: (a) administering to the subject an agent which downregulates an activity or expression of a coagulation factor or an effector thereof; and (b) harvesting the hematopoietic precursors from the peripheral blood.
    Type: Grant
    Filed: September 5, 2010
    Date of Patent: April 4, 2017
    Assignees: Yeda Research and Development Co. Ltd., Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anna Aronovich, Dalit Tchorsh-Yutsis, Gideon Rechavi, Yair Reisner